Replies to post #33641 on Biotech Values

[DewDiligence]

FDA Approves Fragmin for Thrombosis in Cancer Patients

[Fragmin is a low-molecular-weight heparin that has always taken a back seat to Lovenox despite the fact that it is marketed by PFE. This approval is a label expansion that will probably result in only a modest sales increase. Interestingly, the FDA originally wanted to reject Fragmin for cancer but acquiesced to convening ODAC, which voted 12-0 to approve it (#msg-13149707).]

http://biz.yahoo.com/ap/070502/pfizer_fda.html?.v=2

>>
Pfizer and Eisai Receive Additional FDA Approval for Fragmin

Wednesday May 2, 2:15 pm ET

NEW YORK (AP) -- Pfizer Inc. and Eisai Co. said Wednesday the Food and Drug Administration approved Fragmin for use in treating recurrent blood clots in cancer patients.

The drug is already approved to treat deep-vein thrombosis, also a type of blood clot, in patients undergoing hip replacement surgery and in at-risk patients undergoing abdominal surgery.
<<